MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 573707 | Name: Altinicline maleate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Altinicline maleate is a potent neuronal nicotinic ACh receptor agonist that improves cognitive function in a MPTP-induced model of Parkinson's Disease in vivo.

Chemical Structure

Altinicline maleate
Altinicline maleate
CAS#192231-16-6 (maleate)

Theoretical Analysis

MedKoo Cat#: 573707

Name: Altinicline maleate

CAS#: 192231-16-6 (maleate)

Chemical Formula: C16H18N2O4

Exact Mass: 0.0000

Molecular Weight: 302.33

Elemental Analysis: C, 63.56; H, 6.00; N, 9.27; O, 21.17

Price and Availability

Size Price Availability Quantity
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
192231-16-6 (maleate) 179120-92-4 (free base)
Synonym
Altinicline maleate; SIB-1508Y maleate; SIB1508Y maleate; SIB 1508Y maleate;
IUPAC/Chemical Name
(S)-3-ethynyl-5-(1-methylpyrrolidin-2-yl)pyridine maleate
InChi Key
BCPPKHPWLRPWBJ-OURKGEEVSA-N
InChi Code
InChI=1S/C12H14N2.C4H4O4/c1-3-10-7-11(9-13-8-10)12-5-4-6-14(12)2;5-3(6)1-2-4(7)8/h1,7-9,12H,4-6H2,2H3;1-2H,(H,5,6)(H,7,8)/b;2-1-/t12-;/m0./s1
SMILES Code
CN1[C@H](C2=CN=CC(C#C)=C2)CCC1.O=C(O)/C=C\C(O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
(EC50 values are 1.8, 5, 9 and 23 nM for α4β2, α2β4, α4β4 and α3β4 receptors respectively)

Preparing Stock Solutions

The following data is based on the product molecular weight 302.33 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Rao TS, Adams PB, Correa LD, Santori EM, Sacaan AI, Reid RT, Cosford ND. Pharmacological characterization of (S)-(2)-5-ethynyl-3-(1-methyl-2-pyrrolidinyl)pyridine HCl (SIB-1508Y, Altinicline), a novel nicotinic acetylcholine receptor agonist. Brain Res. 2008 Oct 9;1234:16-24. doi: 10.1016/j.brainres.2008.07.063. Epub 2008 Jul 28. PMID: 18692487. 2: Cosford ND, Bleicher L, Vernier JM, Chavez-Noriega L, Rao TS, Siegel RS, Suto C, Washburn M, Lloyd GK, McDonald IA. Recombinant human receptors and functional assays in the discovery of altinicline (SIB-1508Y), a novel acetylcholine-gated ion channel (nAChR) agonist. Pharm Acta Helv. 2000 Mar;74(2-3):125-30. doi: 10.1016/s0031-6865(99)00024-2. PMID: 10812948. 3: Wagner FF, Comins DL. Expedient five-step synthesis of SIB-1508Y from natural nicotine. J Org Chem. 2006 Oct 27;71(22):8673-5. doi: 10.1021/jo0616052. PMID: 17064057. 4: Schneider JS, Van Velson M, Menzaghi F, Lloyd GK. Effects of the nicotinic acetylcholine receptor agonist SIB-1508Y on object retrieval performance in MPTP-treated monkeys: comparison with levodopa treatment. Ann Neurol. 1998 Mar;43(3):311-7. doi: 10.1002/ana.410430308. PMID: 9506547. 5: Parkinson Study Group. Randomized placebo-controlled study of the nicotinic agonist SIB-1508Y in Parkinson disease. Neurology. 2006 Feb 14;66(3):408-10. doi: 10.1212/01.wnl.0000196466.99381.5c. PMID: 16476941. 6: Cosford ND, Bleicher L, Herbaut A, McCallum JS, Vernier JM, Dawson H, Whitten JP, Adams P, Chavez-Noriega L, Correa LD, Crona JH, Mahaffy LS, Menzaghi F, Rao TS, Reid R, Sacaan AI, Santori E, Stauderman KA, Whelan K, Lloyd GK, McDonald IA. (S)-(-)-5-ethynyl-3-(1-methyl-2-pyrrolidinyl)pyridine maleate (SIB-1508Y): a novel anti-parkinsonian agent with selectivity for neuronal nicotinic acetylcholine receptors. J Med Chem. 1996 Aug 16;39(17):3235-7. doi: 10.1021/jm960328w. PMID: 8765504. 7: Sacaan AI, Reid RT, Santori EM, Adams P, Correa LD, Mahaffy LS, Bleicher L, Cosford ND, Stauderman KA, McDonald IA, Rao TS, Lloyd GK. Pharmacological characterization of SIB-1765F: a novel cholinergic ion channel agonist. J Pharmacol Exp Ther. 1997 Jan;280(1):373-83. PMID: 8996218. 8: Schneider JS, Tinker JP, Van Velson M, Menzaghi F, Lloyd GK. Nicotinic acetylcholine receptor agonist SIB-1508Y improves cognitive functioning in chronic low-dose MPTP-treated monkeys. J Pharmacol Exp Ther. 1999 Aug;290(2):731-9. PMID: 10411585. 9: Grottick AJ, Trube G, Corrigall WA, Huwyler J, Malherbe P, Wyler R, Higgins GA. Evidence that nicotinic alpha(7) receptors are not involved in the hyperlocomotor and rewarding effects of nicotine. J Pharmacol Exp Ther. 2000 Sep;294(3):1112-9. PMID: 10945867. 10: Grottick AJ, Haman M, Wyler R, Higgins GA. Reversal of a vigilance decrement in the aged rat by subtype-selective nicotinic ligands. Neuropsychopharmacology. 2003 May;28(5):880-7. doi: 10.1038/sj.npp.1300102. Epub 2003 Mar 5. PMID: 12637951. 11: Barker G, McGrath JL, Klapars A, Stead D, Zhou G, Campos KR, O'Brien P. Enantioselective, palladium-catalyzed α-arylation of N-Boc pyrrolidine: in situ react IR spectroscopic monitoring, scope, and synthetic applications. J Org Chem. 2011 Aug 5;76(15):5936-53. doi: 10.1021/jo2011347. Epub 2011 Jul 8. PMID: 21714542. 12: Ferguson SM, Brodkin JD, Lloyd GK, Menzaghi F. Antidepressant-like effects of the subtype-selective nicotinic acetylcholine receptor agonist, SIB-1508Y, in the learned helplessness rat model of depression. Psychopharmacology (Berl). 2000 Oct;152(3):295-303. doi: 10.1007/s002130000531. PMID: 11105940. 13: Menzaghi F, Whelan KT, Risbrough VB, Rao TS, Lloyd GK. Interactions between a novel cholinergic ion channel agonist, SIB-1765F and L-DOPA in the reserpine model of Parkinson's disease in rats. J Pharmacol Exp Ther. 1997 Jan;280(1):393-401. PMID: 8996220. 14: Schneider JS, Pope-Coleman A, Van Velson M, Menzaghi F, Lloyd GK. Effects of SIB-1508Y, a novel neuronal nicotinic acetylcholine receptor agonist, on motor behavior in parkinsonian monkeys. Mov Disord. 1998 Jul;13(4):637-42. doi: 10.1002/mds.870130405. PMID: 9686767. 15: Menzaghi F, Whelan KT, Risbrough VB, Rao TS, Lloyd GK. Effects of a novel cholinergic ion channel agonist SIB-1765F on locomotor activity in rats. J Pharmacol Exp Ther. 1997 Jan;280(1):384-92. PMID: 8996219. 16: Grottick AJ, Wyler R, Higgins GA. The alpha4beta2 agonist SIB 1765F, but not the alpha7 agonist AR-R 17779, cross-sensitises to the psychostimulant effects of nicotine. Psychopharmacology (Berl). 2000 Jun;150(2):233-6. doi: 10.1007/s002130000444. PMID: 10907678.

View History

Altertenuol

Altertenuol